Objective To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate
dosage (15 mg/m 2 /week) versus a higher dosage (30 mg/m 2 /week) in patients with …

Objectives To validate the previously proposed classification criteria for Henoch–Schönlein
purpura (HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener granulomatosis (c-WG) …

Objective. To identify a core set of outcome variables for the assessment of children with
juvenile arthritis (JA), to use the core set to develop a definition of improvement to determine …

Background: There has been a lack of appropriate classification criteria for vasculitis in
children. Objective: To develop a widely accepted general classification for the vasculitides …

Juvenile idiopathic arthritis (JIA) is defined by the International League of Associations for
Rheumatology (ILAR) as arthritis of unknown etiology that begins before the sixteenth birthday …

Objective To develop and validate a composite disease activity score for juvenile idiopathic
arthritis (JIA), the Juvenile Arthritis Disease Activity Score (JADAS). Methods The JADAS …

Background Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods We …

OBJECTIVE: To develop preliminary criteria for inactive disease and clinical remission for
select categories of juvenile idiopathic arthritis (JIA), and to decide what such clinical states …

Background Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid
arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF …

Objective To develop criteria for the classification of macrophage activation syndrome (MAS)
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, …